Sanofi Debt to Equity Ratio 2010-2024 | SNY

Current and historical debt to equity ratio values for Sanofi (SNY) over the last 10 years. The debt/equity ratio can be defined as a measure of a company's financial leverage calculated by dividing its long-term debt by stockholders' equity. Sanofi debt/equity for the three months ending March 31, 2024 was 0.19.
Sanofi Debt/Equity Ratio Historical Data
Date Long Term Debt Shareholder's Equity Debt to Equity Ratio
2024-03-31 $0.00B 0.00
2023-12-31 $56.40B $80.47B 0.70
2023-09-30 $0.00B 0.00
2023-06-30 $57.14B $79.54B 0.72
2023-03-31 $0.00B 0.00
2022-12-31 $54.33B $79.18B 0.69
2022-09-30 $0.00B 0.00
2022-06-30 $53.77B $75.88B 0.71
2022-03-31 $0.00B 0.00
2021-09-30 $0.00B 0.00
2021-06-30 $58.99B $76.35B 0.77
2021-03-31 $0.00B 0.00
2020-09-30 $0.00B 0.00
2020-03-31 $0.00B 0.00
2019-09-30 $0.00B 0.00
2019-03-31 $0.00B 0.00
2018-03-31 $0.00B 0.00
2017-12-31 $46.98B $65.85B 0.71
2017-09-30 $0.00B 0.00
2017-06-30 $48.50B $63.58B 0.76
2017-03-31 $0.00B 0.00
2016-12-31 $51.95B $63.88B 0.81
2016-09-30 $0.00B 0.00
2016-06-30 $50.57B $61.39B 0.82
2016-03-31 $0.00B 0.00
2015-09-30 $0.00B 0.00
2015-06-30 $45.52B $62.80B 0.73
2014-06-30 $53.44B $71.01B 0.75
2013-06-30 $53.27B $73.39B 0.73
2012-06-30 $58.33B $72.42B 0.81
2012-03-31 $0.00B $0.00B 0.00
2011-12-31 $60.97B $78.54B 0.78
2011-09-30 $0.00B 0.00
2011-06-30 $67.62B $75.69B 0.89
2011-03-31 $0.00B 0.00
2010-12-31 $42.46B $70.76B 0.60
2010-09-30 $0.00B 0.00
2010-06-30 $42.97B $67.09B 0.64
2010-03-31 $0.00B 0.00
2009-12-31 $44.07B $67.56B 0.65
2009-09-30 $0.00B 0.00
2009-06-30 $43.55B $61.00B 0.71
2009-03-31 $0.00B 0.00
Sector Industry Market Cap Revenue
Medical Large Cap Pharmaceutical $119.456B $46.611B
Sanofi-Aventis manufactures & markets prescription drugs across countries. It focuses on major therapeutic areas such as multiple sclerosis, cardiovascular, immunology, neurology, oncology, rare blood disorders & diabetes, etc. By taking Genzyme Corporation as a subsidiary, it added products like Cerezyme, Myozyme/Lumizyme & Fabrazyme to its portfolio. Sanofi has become a major player in the CHC sector. It acquired many companies i.e. Ablynx & Bioverativ, Synthorx & Principia & Translate Bio and Kadmon. It has collaborated with companies like Regeneron among others. It develops and markets Dupixent, Kevzara & Libtayo in collaboration with Regeneron. Sanofi, along with Regeneron, is now solely responsible for Praluent marketing in & outside the U.S. Sanofi operates through 3 Global Business Units: Specialty Care (neurology & immunology, rare diseases, rare blood disorders & oncology), Vaccines & General Medicines (diabetes, cardiovascular & established products) and Consumer Healthcare, a standalone unit.
Stock Name Country Market Cap PE Ratio
Eli Lilly (LLY) United States $847.248B 122.45
Novo Nordisk (NVO) Denmark $631.845B 48.55
Johnson & Johnson (JNJ) United States $350.533B 13.92
Merck (MRK) United States $324.174B 58.98
AbbVie (ABBV) United States $302.599B 15.64
AstraZeneca (AZN) United Kingdom $243.139B 21.14
Novartis AG (NVS) Switzerland $214.497B 15.21
Pfizer (PFE) United States $155.321B 19.30
Innoviva (INVA) United States $1.013B 7.11